Ysios Capital, a Spanish enterprise capital agency specialising in life sciences, as we speak introduced the launch of InceptionBio, a brand new fund with a goal measurement of €100 million targeted on BioTech firm creation and early-stage challenge growth.
The fund has already accomplished its first closing, with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) by means of its SICC Innvierte programme, which helps funding in high-potential progressive firms. Joan Perelló, Managing Companion at Ysios Capital, will lead the fund, alongside companion Arturo Urrios.
“Spain has world-class science and a novel alternative to translate that science into globally impactful BioTech firms. With InceptionBio, we intention to additional strengthen our capability to have interaction on the earliest levels of innovation, working carefully with the scientific ecosystem to construct firms that may ship significant options for sufferers,” stated Joan Perelló, Managing Companion at Ysios Capital.
Based in 2008, Ysios Capital manages over €400 million in property by means of its three enterprise capital funds and likewise acts as funding advisor to Telescope Biotech Fund, a listed BioTech fund managed by Andbank Wealth Administration.
The VC agency affords personal fairness funding to early- and mid-stage life science firms growing remedies that considerably affect sufferers, specializing in areas with excessive unmet medical wants.
InceptionBio will concentrate on figuring out, growing and constructing new firms round high-quality science, with a specific concentrate on Spain. The brand new fund will primarily put money into know-how switch alternatives and early-stage firms. This can allow Ysios to work carefully with universities, analysis centres, and scientific entrepreneurs to speed up the interpretation of scientific discoveries into new therapies.
CDTI-Innvierte’s help enhances public-private collaboration in a key sector for Spain’s BioTech ecosystem. The VC agency states that this helps in accelerating know-how switch, encouraging the event of high-growth, innovation-driven firms, and boosting the competitiveness of Spain’s R&D system.
The fund at present has a pipeline of funding alternatives beneath superior evaluate and goals to help the creation of no less than three new BioTech firms in 2026.
In accordance with Ysios, InceptionBio’s technique includes creating new firms primarily based on scientific property from universities and analysis centres, whereas additionally figuring out and attracting worldwide property that may be developed in Spain.
Via this technique, Ysios plans to bolster the Spanish BioTech ecosystem and set up Spain as a number one hub on this sector. This new technique enhances Ysios Capital’s funding method and broadens early-stage engagement. With the launch of InceptionBio, Ysios goals to additional broaden its capability to help biomedical innovation, ranging from firm creation by means of later-stage growth.
“We see a big alternative to establish differentiated scientific property, translate them into high-potential firms, and entice the expertise and capital wanted to develop them. InceptionBio was created to attach science, entrepreneurship and funding, working carefully with each the private and non-private sectors to speed up firm creation throughout Europe, with a transparent concentrate on Spain,” stated Arturo Urrios, Companion at Ysios Capital.
Ysios Capital has invested in additional than 40 BioTech firms and has accomplished six NASDAQ exits and ten M&A transactions. The agency has participated in main Spanish BioTech transactions, together with investments in Tigenix/Cellerix, Sanifit, STAT-Diagnostica, Ona Therapeutics, SpliceBio, and Minoryx Therapeutics. It has additionally performed a key position in distinguished offers like Takeda’s acquisition of Tigenix (€450 million), Qiagen’s buy of STAT-Diagnostica (€172 million), and Vifor Pharma’s Sanifit acquisition (€375 million).
